Worldwide, the incidence of major depressive disorder (MDD) is increasing annually,
resulting in greater economic and social burdens. Moreover, the pathological mechanisms …

Biobanks often contain several phenotypes relevant to diseases such as major depressive
disorder (MDD), with partly distinct genetic architectures. Researchers face complex …

Early life stress (ELS), characterized as abuse, neglect, and abandonment, can cause
several adverse consequences in the lives of affected individuals. ELS experiences can …

Background MicroRNAs (miRNAs) and circulating cell-free mitochondrial DNA (ccf-mtDNA)
have attracted interest as biological markers of affective disorders. In response to stress, it is …

Objective: Major depressive disorder (MDD) is highly heterogeneous. Standard typology
partly captures the disorder's symptomatic heterogeneity, although whether it adequately …

Background Major depressive disorder (MDD) has a significant impact on global burden of
disease. Complications in clinical management can occur when response to …

Individual treatment outcomes to antidepressants varies widely, yet the determinants to this
difference remain elusive. MicroRNA (miRNA) gene expression regulation in major …

Bupropion (Bup) belongs to the norepinephrine–dopamine reuptake inhibitor (NDRI) class
and it is the only FDA-approved drug of its class for the treatment of major depressive …

There is a two-fold higher incidence of depression in females compared to men with recent
studies suggesting a role for microglia in conferring this sex-dependent depression risk. In …

Background Attention-deficit/hyperactivity disorder (ADHD) and major depressive disorder
(MDD) are two highly prevalent disorders that frequently co-occur. Prior evidence from …